Medarex Snapshot
Medarex is building the ultimate monoclonal antibody. Its UltiMAb technology utilizes transgenic mice whose antibody gene expression is suppressed to create fully human antibodies. Medarex has more than 40 developed or licensed antibodies for cancer, rheumatoid arthritis, and other autoimmune, inflammatory, and infectious diseases in clinical trials or pre-trial stages. The company has partnerships with numerous with pharma and biotech firms including Genmab, which has licensed antibody therapies for leukemia, psoriasis, and other conditions. Other development partners include Pfizer, Amgen, Bristol-Myers Squibb, Eli Lilly, and Kirin's pharma unit.
